Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T14:10:41.078Z.
Calculation as of: 2026-10-06T14:10:41.078Z.
Quote observation: 2026-10-06T14:10:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ca6b3f945453907090b614e1109f6f6fce8b12406cb587c45253d0481e46e17d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$33.24M
Price/FCF Ratio
N/A
TTM Avg
507.99
3Y Avg
507.99
5Y Avg
507.99
Market Cap
$31.62M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$31.23M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | $32.92M | N/A | N/A | N/A | N/A |
| EUDA Health Holdings Limited (EUDA)vs › | $33.24M | N/A | 507.99 | 507.99 | 507.99 |
| HeartBeam, Inc. (BEAT)vs › | $33.31M | N/A | N/A | N/A | N/A |
| Context Therapeutics Inc. (CNTX)vs › | $32.19M | N/A | N/A | N/A | N/A |
| Grace Therapeutics, Inc. (GRCE)vs › | $34.01M | N/A | N/A | N/A | N/A |
| MIRA Pharmaceuticals, Inc. (MIRA)vs › | $31.62M | N/A | N/A | N/A | N/A |
| BeyondSpring Inc. (BYSI)vs › | $31.46M | N/A | N/A | N/A | N/A |
| Baird Medical Investment Holdings Limited (BDMD)vs › | $31.23M | N/A | N/A | N/A | N/A |
| MDxHealth S.A. (MDXH)vs › | $30.86M | N/A | N/A | N/A | N/A |
| BriaCell Therapeutics Corp. (BCTX)vs › | $35.58M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
